(Q43757715)

English

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Tahamtan Ahmadi

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Elise A Chong

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Amanda Gordon

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Nicole A Aqui

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sunita D Nasta

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Jakub Svoboda

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Anthony R Mato

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Stephen J Schuster

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

language of work or name

0 references

publication date

7 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

120

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

222-228

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Myocarditis during lenalidomide therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28405

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28405

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

release_72wvkinl4rhyjfvqt7fauq5q3q

1 reference

https://api.fatcat.wiki/v0/release/72wvkinl4rhyjfvqt7fauq5q3q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43757715&oldid=2103081857"